Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MdxHealth : MDxHealth to Present at the 2013 BIO CEO & Investor Conference



  MdxHealth : MDxHealth to Present at the 2013 BIO CEO & Investor Conference

IRVINE, CA,  and  LIEGE, BELGIUM  -  February 4,  2013  - MDxHealth  SA  (NYSE 
Euronext: MDXH),  a leading  molecular diagnostic  company that  develops  and 
commercializes epigenetic  tests to  support cancer  diagnosis and  treatment, 
today announced that Dr. Jan Groen  , the Company's  Chief Executive  Officer, 
will present at  the 15^th  Annual BIO CEO  & Investor  Conference on  Monday, 
February 11th 2013  at 3.00  pm  Eastern Time  at the  Waldorf-Astoria in  New 
York, NY.

About the BIO CEO & Investors Conference
The Annual BIO CEO  & Investor Conference is  the largest investor  conference 
focused on established  and emerging publicly  traded biotech companies.  This 
year's conference  will feature  corporate presentations  from more  than  130 
leading biotechnology and pharmaceutical  companies. The presenting  companies 
consist of a selection of mid- to large-cap established public companies  from 
around the globe, who typically have a clinical stage program centered  around 
therapeutics, molecular diagnostics, or a  platform technology, as well as  an 
upcoming clinical, regulatory, or corporate catalyst. More information on  the 
conference can be found at  www.bio.org.

About MDxHealth
MDxHealth is a molecular diagnostics company that develops and  commercializes 
advanced epigenetic tests for cancer assessment and the personalized treatment
of patients.  The  company's  first commercial  product,  the  ConfirmMDx  for 
Prostate Cancer test, has been shown  to help distinguish patients who have  a 
true-negative biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer diagnosis and
treatment information. The  company has  a proprietary platform  and a  strong 
epigenetic product pipeline focused on  the development of products for  brain 
and lung cancers. The company is  based in Irvine, California with a  European 
headquarters in Liege, Belgium. For  more information visit MDxHealth  website 
at www.mdxhealth.com.

Contacts 

Company :                                  
Dr Jan Groen, CEO                                       
MDxHealth                                                              
US: +1 949 812 6979                           
BE: +32 4 364 20 70                            
info@mdxhealth.com  

Media :
Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955 
US: +1 646 378 2952
Cell: +44 7968 022075
msinclair@halsin.com

Investors :
Seth Lewis
The Trout Group
US : + 1 646 378 2952
slewis@troutgroup.com

This press  release contains  forward-looking  statements and  estimates  with 
respect to the anticipated future performance  of MDxHealth and the market  in 
which it operates. Such statements and estimates are based on assumptions  and 
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable  but may  not prove to  be correct.  Actual events  are 
difficult to predict, may  depend upon factors that  are beyond the  company's 
control, and  may turn  out to  be materially  different. MDxHealth  expressly 
disclaims any obligation to update any such forward-looking statements in this
release to reflect any change in  its expectations with regard thereto or  any 
change in events, conditions or circumstances  on which any such statement  is 
based unless required by law or regulation.

BIO CEO ENG

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MdxHealth via Thomson Reuters ONE
HUG#1675036
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement